Growth Investment Partners (GIP) Ghana Ltd, an investment platform established by British International Investment (BII), has announced a strategic investment in mPharma Ghana Ltd to enhance access to affordable medicines and primary healthcare across West Africa.
The investment will support mPharma’s operations in Ghana and drive its expansion into Francophone West Africa, particularly in Togo and Benin. The initiative seeks to strengthen healthcare systems in the region by improving inventory management and scaling up mPharma’s QualityRx franchise model, which empowers local pharmacies to provide community-based healthcare.
Speaking at the announcement, Mr. Jacob Kholi, Chief Executive and Investment Officer of GIP Ghana, said the partnership aligns with GIP’s mission to back impactful businesses that deliver essential services to ordinary people. He noted that expanding mPharma’s reach in Francophone countries would increase access to affordable medicines and bolster regional healthcare resilience.
Founded in 2013, mPharma has become one of Africa’s leading healthcare providers, managing a network of mutti pharmacies and offering services such as mutti Doctor, a virtual consultation and screening platform that reduces patient wait times and supports early diagnosis of chronic diseases.
Mr. Kwesi Arhin, Chief Executive Officer of mPharma, said the new funding will enable the company to deepen partnerships with pharmacies and healthcare providers across West Africa. “With GIP’s support, we can continue to improve patient care and ensure equitable access to quality medicines throughout Ghana and Francophone West Africa,” he said.
British International Investment, a long-term investor in mPharma, expressed confidence in the company’s potential. Mr. Kwabena Asante-Poku, BII’s Country Director for Ghana, said the partnership would accelerate mPharma’s growth in Francophone markets while strengthening health systems and expanding access to essential services.
mPharma’s mutti membership programme has grown rapidly—from under 10,000 members in 2019 to more than 400,000 by the end of 2024. Over 70 per cent of members report lower drug prices, while 75 per cent say they no longer experience stockouts of essential medicines.
The company also runs specialised programmes in chronic disease management, women’s health, and child healthcare. Its Diabetes Test & Treat initiative has achieved blood sugar control in 80 per cent of patients within six months. Partnerships with pharmaceutical companies such as Pfizer have helped secure discounts of up to 65 per cent on life-saving drugs.
Established in 2023 with an anchor capital of up to US$50 million from BII, GIP Ghana provides long-term, flexible financing to bridge Ghana’s SME funding gap and promote sustainable economic growth.
mPharma currently operates in six African countries, including Ghana, Togo, and Benin, leveraging technology and community-based models to transform access to quality healthcare across the continent.
